HeartBeam Receives FDA 510(k) Clearance, Prepares to Launch 12-Lead ECG Device
"The fourth quarter of 2025 and early 2026 were transformational for HeartBeam, culminating in the FDA 510(k) Clearance for our 12-Lead ECG synthesis software. With that clearance, we are now prepared to start a limited commercial launch for our credit card sized 12-lead ECG device in the arrhythmia market," said Robert Eno, Chief Executive Officer, HeartBeam. "HeartBeam's technology is a true platform. We believe that our unique and patented technology is the only way for patients to obtain a 12-lead ECG at home or wherever they have symptoms, through a small, easy to use, cable free device. Our core technology can be applied to multiple form factors. In the background, we also have been developing a second form factor, an on-demand 12-lead patch. We believe that this can disrupt the long-term continuous monitor and mobile cardiac telemetry, or MCT markets, a combined $2B revenue market with established reimbursement. The technology in these two form factors has the potential to enable a full range of 12-lead ECG capabilities, including arrhythmia, heart attack detection, and personalized AI algorithms. Through our platform, we are creating an ecosystem that will add unique insights and actionable data for both patients and physicians that are unavailable elsewhere and add to the premium offering of HeartBeam. We are incredibly excited by the progress made to date on our key growth initiatives and look forward to providing updates as we continue to execute on our vision," concluded Eno.
